| Bioactivity | GDC-6599 (Example 8) is an orally active TRPA1 inhibitor. GDC-6599 can be used to study TRPA1-mediated diseases such as pain[1]. |
| Target | TRPA1. |
| Name | GDC-6599 |
| CAS | 2376824-99-4 |
| Formula | C20H19ClN6O3 |
| Molar Mass | 426.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jack Alexander Terrett, et al. Oxadiazole transient receptor potential channel inhibitors. Patent US20190284179A1. |
GDC-6599
CAS: 2376824-99-4 F: C20H19ClN6O3 W: 426.86
GDC-6599 (Example 8) is an orally active TRPA1 inhibitor. GDC-6599 can be used to study TRPA1-mediated diseases such as
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.